Pharmaceutical Portfolio Strategy

Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Conferences 2021

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Drive commercial success

drive commerical success pharma intelligence

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
Country-specific treatment algorithms and reimbursement scenarios
Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

Relevant products

Discover the power of Pharma360

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Pharmapremia: Benchmark better and optimize your drug development pipeline

Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.

Key benefits:

Manage portfolio risks
Analyze success factors
Create meaningful benchmarks

View all content

In Vivo

Critical Insights into Market Access

18 Aug 2021

Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

View infographic
In Vivo

‘We Have A Lot Of Work To Do,’ Says Head Of HIV + Hepatitis Policy Institute

By William Masters 16 Aug 2021

Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.

View article
In Vivo

Biotechs Choosing Brazil For Drug Development And Early Sales

By Mark Ratner 12 Aug 2021

Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.

View article
Datamonitor Healthcare, Biomedtracker, Scrip

2021 Post-ASCO Insights and Analysis

11 Aug 2021

The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

Topic Cancer

Single report
Pharma 360

Global Oncology Opportunities & Trends 2025: Key Markets, Indications and Products

06 Jul 2021

Join Informa Pharma Intelligence for the “Global Oncology Opportunities” webinar!

View article
Datamonitor Healthcare

Top 10 Best-Selling Drugs of 2020

02 Jul 2021

One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed.

Topic Drug Review Drug Pricing

View article
In Vivo

Rising Leaders 2021

27 May 2021

Gain insights into managing unexpected events, effectively communicating change, executing crisis management plans, and more. Industry experts share their insights into innovative ways to integrate teams after M&A, manage D&I initiatives, and build strong leadership for a changing workforce.

Topic Leadership

View article
In Vivo, Pink Sheet

Manufacturing and Distribution: Challenges and Opportunities

13 May 2021

The COVID-19 pandemic has brought about significant manufacturing and distribution challenges and opportunities for Pharma. Seize new opportunities and avoid risk with the strategic commercial and regulatory intelligence you need to stay competitive by subscribing to Pink Sheet and In Vivo.

Topic Strategy

View article
Citeline, Biomedtracker, Pharma Consulting, Datamonitor Heal...

COVID-19 24 hour webinar recordings

30 Apr 2021

Catch up on any missed COVID-19 24 hour webinar sessions

Topic Cardiovascular Coronavirus

Full video
In Vivo

COVID-19 Made Its Mark On the R&D Pipeline And Novel Drug Launches In 2020

By Alex Shimmings 20 Apr 2021

A new analysis reveals the impact of the coronavirus pandemic on pharma R&D in 2020 in two quarters: the total size of the pipeline and in the number of novel products launched in their first markets.

View article
In Vivo

Pandemic Puts A Spotlight On Counterfeit Drugs

By William Masters 13 Apr 2021

As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.

View article
In Vivo

The 14 Billion Dose COVID-19 Manufacturing Challenge

By Andrew McConaghie 25 Mar 2021

Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.

View article
In Vivo

Merck & Co, Indian Firms On Tackling Supply Chain Risks And A Hijack

By Anju Ghangurde 16 Mar 2021

Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.

View article
In Vivo

Deal Making Trends 2021

10 Mar 2021

Despite the chaos felt in many other sectors during the COVID-19 pandemic, pharma IPOs experienced a banner year in 2020. Understand deal making trends and business strategies as In Vivo examines the emergence of special purpose acquisition companies (SPACs) in a data-packed infographic

Topic Business Strategies

Single report
In Vivo

At War With A Pandemic: Manufacturing For Our Lives

By Joanne Shorthouse 10 Mar 2021

The rapid development of a vaccine to fight COVID-19 is an effort that will be discussed and admired for centuries to come. The effort to make and deliver the vaccines to those who are most at risk is a battle all of its own. Two manufacturers talk to In Vivo about managing roll out strategies when the whole world is watching.

View article